Investigation into MoonLake Immunotherapeutics for Potential Securities Law Violations

Strategic Insights -

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on treating inflammatory skin and joint diseases, is under investigation by leading securities law firm Bleichmar Fonti & Auld LLP for potential violations of federal securities laws. The investigation stems from disappointing results of the company's Phase 3 VELA trials for its investigational therapeutic sonelokimab, which led to a significant decline in MoonLake's stock price. Investors who invested in MoonLake are encouraged to submit their information to the firm, which represents plaintiffs in securities class actions and shareholder litigation.

Key Takeaways:

  • MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating inflammatory skin and joint diseases.
  • The company's investigational therapeutic sonelokimab is being investigated for potential efficacy in treating inflammatory diseases, specifically moderate to severe hidradenitis suppurativa.
  • The Phase 3 VELA trials for sonelokimab reported disappointing results, questioning the drug's chances for regulatory approval and commercial viability.
  • On September 29, 2025, MoonLake's stock price plummeted by $55.75 per share, or nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025.
  • Bleichmar Fonti & Auld LLP is investigating potential securities law violations, and investors may have legal options.
  • The firm will seek court approval for any potential fees and expenses, with no cost to investors.
  • The firm's recent notable successes include recovering over $900 million from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.

Statistics:

  • MoonLake's stock price fell by $55.75 per share on September 29, 2025.
  • The price decline translates to a nearly 90% decrease from $61.99 on September 28, 2025, to $6.24 on September 29, 2025.
  • Bleichmar Fonti & Auld LLP has recovered over $900 million from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.
  • The firm represents plaintiffs in securities class actions and shareholder litigation.

Sources:

  • Bleichmar Fonti & Auld LLP press release, available on Newsfile Corp. - October 13, 2025.
  • MoonLake Immunotherapeutics website, https://www.moonlakebio.com.
  • The Legal 500, Chambers USA, and ISS SCAS publications recognizing Bleichmar Fonti & Auld LLP as a top plaintiff law firm.
  • Lawdragon, National Law Journal, and Thomson Reuters publications recognizing Bleichmar Fonti & Auld LLP's attorneys.